Novel and Emerging Therapies for Inflammatory Bowel Disease

Inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease are chronic, relapsing and remitting disorders of intestinal inflammation with potential systemic manifestations. Despite the availability of current biologics, such as anti-tumor necrosis factor (anti-TNF), anti-integrins, anti-interleukins and small molecules such as tofacitinib, the rates of primary and secondary treatment failure remain high in IBD. This highlights the importance of continued development of new therapeutic targets and modifications of existing ones to improve the treatment response rates and to also improve the safety profile and tolerability of these medications. In this review we will discuss novel treatment target agents including selective janus kinase (JAK) inhibitors, anti-interleukin (IL) (IL-12/IL-23), leukocyte trafficking/migrating inhibitors (such as sphingosine-1-phosphate receptor modulator) and other small molecules currently in development.

• Publication year

  2021

• Venue

  Frontiers in Pharmacology

• Publication date

  2021-04-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fphar.2021.651415PMID 33935763PMCID 8080036
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Filgotinib as Maintenance Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study

  2021influential reference
• Efficacy and safety

  2021cited by this paper
• Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn's Disease.

  2021cited by this paper
• Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study

  2021cited by this paper
• Efficacy and Safety of Filgotinib as Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study

  2021cited by this paper
• OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension study

  2020cited by this paper
• JAK–STAT pathway targeting for the treatment of inflammatory bowel disease

  2020cited by this paper
• P420 A randomised, observer-blinded phase Ib multiple, ascending dose study of UTTR1147A, an IL-22Fc fusion protein, in healthy volunteers and ulcerative colitis patients

  2020cited by this paper
• Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme

  2020cited by this paper
• Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.

  2020cited by this paper
• Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.

  2020cited by this paper
• Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.

  2020influential reference
• Efficacy and Safety of Continued Treatment with Mirikizumab in a Phase 2 Trial of Patients with Ulcerative Colitis.

  2020cited by this paper
• Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.

  2020cited by this paper
• Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis.

  2020cited by this paper
• Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.

  2020cited by this paper
• Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.

  2020cited by this paper
• Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis

  2020cited by this paper
• Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program

  2020cited by this paper
• TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial.

  2020cited by this paper
• Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

  2019cited by this paper
• Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis

  2019cited by this paper
• Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

  2019cited by this paper
• 1003 – Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease

  2019cited by this paper
• Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease

  2019cited by this paper
• New biologics and small molecules in inflammatory bowel disease: an update

  2019influential reference
• Targeting mucosal healing in Crohn’s disease: what the clinician needs to know

  2019cited by this paper
• Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

  2019cited by this paper
• DOP48 Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study

  2019cited by this paper
• Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis.

  2019cited by this paper
• Anti-interleukin-23 agents for the treatment of ulcerative colitis

  2019cited by this paper
• Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.

  2019cited by this paper
• DOP062 The anti-MAdCAM antibody SHP647 in Crohn’s disease: Endoscopic effects of induction therapy

  2018cited by this paper
• The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis

  2018cited by this paper
• Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration.

  2018cited by this paper
• Anti-integrin therapy for inflammatory bowel disease

  2018influential reference
• Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

  2018cited by this paper
• Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL‐22Fc): A Potential Therapy for Epithelial Injury

  2018influential reference
• Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.

  2018cited by this paper
• OP024 Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II study

  2018cited by this paper
• OTU-003 Etrolizumab as induction therapy in moderate to severe crohn’s disease: results from bergamot cohort 1

  2018cited by this paper
• Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.

  2017influential reference
• Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

  2017influential reference
• Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial (статья)

  2017cited by this paper
• OP035 Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease.

  2017cited by this paper
• Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?

  2017cited by this paper
• OP011 Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study.

  2017influential reference
• Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.

  2017cited by this paper
• Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease.

  2017cited by this paper
• Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.

  2017cited by this paper
• Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)

  2017cited by this paper
• Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

  2017cited by this paper
• Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

  2017cited by this paper
• The Role of Diet in Inflammatory Bowel Disease

  2017cited by this paper
• Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.

  2017cited by this paper
• Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study

  2017cited by this paper
• Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

  2017cited by this paper
• Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

  2016cited by this paper
• AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial.

  2016cited by this paper
• Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.

  2016cited by this paper
• Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis

  2016cited by this paper
• Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

  2016cited by this paper
• Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.

  2016cited by this paper
• THE ROLE OF DIET IN INFLAMMATORY BOWEL DISEASE

  2015cited by this paper
• Efficacy and Safety of Antiintegrin Antibody for Inflammatory Bowel Disease

  2015cited by this paper
• Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis.

  2015cited by this paper
• Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.

  2014cited by this paper
• Vedolizumab as induction and maintenance therapy for Crohn's disease.

  2013cited by this paper
• Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice.

  2013influential reference
• Vedolizumab as induction and maintenance therapy for ulcerative colitis.

  2013cited by this paper
• Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.

  2012cited by this paper
• Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

  2011cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper
• Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

  2010cited by this paper
• Environmental risk factors for inflammatory bowel disease.

  2010cited by this paper
• Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease.

  2008cited by this paper
• Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

  2008cited by this paper
• Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

  2007cited by this paper
• Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial

  2007cited by this paper
• Maintenance therapy with certolizumab pegol for Crohn's disease.

  2007cited by this paper
• Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

  2006cited by this paper
• The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxide

  2005cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.

  2004cited by this paper
• Infliximab maintenance therapy for fistulizing Crohn's disease.

  2004cited by this paper
• EFFICACY AND SAFETY OF

  2004influential reference
• Cyclic adenosine monophosphate‐responsive elements are involved in the transcriptional activation of the human IL‐10 gene in monocytic cells

  1999cited by this paper
• Environmental risk factors in inflammatory bowel disease.

  1996cited by this paper
• Elevated Cyclic AMP Inhibits NF-κB-mediated Transcription in Human Monocytic Cells and Endothelial Cells*

  1996cited by this paper
• [Crohn's disease].

  1967influential reference
• [Ulcerative colitis].

  1958cited by this paper

• ROS-triggerable dual nanocoated probiotics for inflammatory bowel disease treatment.

  2026cites this paper
• Redrawing the gut map: evolving probiotic approaches to microbiota modulation in inflammatory bowel disease

  2026cites this paper
• Risk of Incident Immune-Mediated Inflammatory Diseases with Second Tumor Necrosis Factor Inhibitor Versus Alternative Biologic Therapy in Patients with Inflammatory Bowel Disease and First TNFi Exposure: A Real-World Cohort Study.

  2025cites this paper
• Gut Virus Axis: Unravelling Viral Contribution to Gut Microbiota Dysbiosis and Translational Medicine in Inflammatory Bowel Disease (IBD)

  2025cites this paper
• Bio-derived nanoplatforms: Emerging strategies for inflammatory bowel disease therapy

  2025cites this paper
• Oral administration of low‐molecular‐weight heparin ameliorates colitis by enhancing the gut mucus barrier via microbial tryptophan metabolites

  2025cites this paper
• Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease.

  2025cites this paper
• Enhancing Tetrahydrocannabinol’s Therapeutic Efficacy in Inflammatory Bowel Disease: The Roles of Cannabidiol and the Cannabinoid 1 Receptor Allosteric Modulator ZCZ011

  2025cites this paper
• Is Deep Remission the Right Time to De-Escalate Biologic Therapy in IBD? A Single-Center Retrospective Study

  2025cites this paper
• Electroacupuncture at ST36 Relieves Visceral Hypersensitivity Based on the Vagus-Adrenal Axis in the Remission Stage of Ulcerative Colitis.

  2025cites this paper
• Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis

  2025cites this paper
• CCR2 overexpressing gingiva mesenchymal stem cells provide high intestinal regeneration in a rat model of ulcerative colitis

  2025cites this paper
• Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.

  2025cites this paper
• Effect of Aegle marmelos Extract-Phospholipid Complexes in Dextran Sulfate Sodium-Induced Ulcerative Colitis in Rats

  2025cites this paper
• Gut, bone, and muscle: the triad of osteosarcopenia in inflammatory bowel disease

  2025cites this paper
• Efficacy and safety of Mirikizumab for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Goat Milk-Derived Extracellular Vesicles Alleviate Colitis Potentially Through Improved Gut Microbiota in Mice

  2025cites this paper
• Chinese herbal medicine‐derived extracellular vesicle‐like particles: Therapeutic potential and future research approaches

  2025cites this paper
• Orally Bioavailable BRD4 BD1 Inhibitor ZL0516 Effectively Suppresses Colonic Inflammation in Animal Models of Inflammatory Bowel Disease.

  2025cites this paper
• S1PR1-biased activation drives the resolution of endothelial dysfunction-associated inflammatory diseases by maintaining endothelial integrity

  2025cites this paper
• Using gut microbiota and non-targeted metabolomics techniques to study the effect of xylitol on alleviating DSS-induced inflammatory bowel disease in mice

  2025cites this paper
• Ovarian cancer recurrence manifested as a solitary intraluminal mass in ileum

  2025cites this paper
• ADS024, a single-strain live biotherapeutic product of Bacillus velezensis alleviates dextran sulfate-mediated colitis in mice, protects human colonic epithelial cells against apoptosis, and maintains epithelial barrier function

  2024cites this paper
• Evaluation of emergency hospital admissions for inflammatory bowel disease as a possible marker of quality of care of British IBD inflammatory bowel disease units

  2024cites this paper
• Alleviating effect of Nexrutine on mucosal inflammation in mice with ulcerative colitis: Involvement of the RELA suppression

  2024cites this paper
• Nanotechnology-enabled M2 macrophage polarization and ferroptosis inhibition for targeted inflammatory bowel disease treatment.

  2024cites this paper
• Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease

  2024cites this paper
• Review of the Potential of Probiotics in Disease Treatment: Mechanisms, Engineering, and Applications

  2024cites this paper
• Drug Repositioning of Inflammatory Bowel Disease Based on Co-Target Gene Expression Signature of Glucocorticoid Receptor and TET2

  2024cites this paper
• Risk of Infection in Patients With Inflammatory Bowel Disease Treated With Interleukin-Targeting Agents: A Systematic Review and Meta-Analysis.

  2024cites this paper
• The Long View: 2-Year Outcomes of Mirikizumab for Ulcerative Colitis.

  2024cites this paper
• Transcription suppression of GABARAP mediated by lncRNA XIST-EZH2 interaction triggers caspase-11-dependent inflammatory injury in ulcerative colitis.

  2024cites this paper
• Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future

  2024cites this paper
• Helminths in alternative therapeutics of inflammatory bowel disease

  2024cites this paper
• Safety, Pharmacokinetics, and Clinical Efficacy of ADS051, a Neutrophil Modulator, in Ulcerative Colitis: Results of a Randomized Phase 1b Trial

  2024cites this paper
• Comprehensive Assessment of Cannabidiol and HU308 in Acute and Chronic Colitis Models: Efficacy, Safety, and Mechanistic Innovations

  2024influential citation
• Probiotics for inflammatory bowel disease: Is there sufficient evidence?

  2024cites this paper
• Exploring the Connections: Autophagy, Gut Microbiota, and Inflammatory Bowel Disease Pathogenesis

  2024cites this paper
• Small-Molecule Neutrophil Modulator ADS051 is Safe and Well-Tolerated in a Phase 1 Single Ascending Dose Study

  2024cites this paper
• The potential of targeting TREM-1 in IBD.

  2024cites this paper
• Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis

  2024cites this paper
• Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease.

  2024cites this paper
• Gut Microbiome-Related Anti-Inflammatory Effects of Aryl Hydrocarbon Receptor Activation on Inflammatory Bowel Disease

  2024cites this paper
• Recent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases

  2024cites this paper
• Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis

  2024cites this paper
• Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study

  2024cites this paper
• Roseburia intestinalis‐derived extracellular vesicles ameliorate colitis by modulating intestinal barrier, microbiome, and inflammatory responses

  2024cites this paper
• Discordant effects of Janus kinases inhibition ex-vivo on inflammatory responses in colonic compared to ileal mucosa.

  2024cites this paper
• Saffron as a Promising Therapy for Inflammatory Bowel Disease

  2024cites this paper
• Inflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia

  2024cites this paper
• Healthcare resource utilization following ustekinumab initiation among bio-naïve Canadian patients with moderately-to-severely active Crohn's disease.

  2024cites this paper
• Predictors of histologic remission in patients with biologic-naïve, moderate-to-severe ulcerative colitis treated with first-line biologic agents and small-molecule drugs: a single-center, retrospective cohort study

  2024influential citation
• Characterization and optimization of variability in a human colonic epithelium culture model.

  2024cites this paper
• Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials

  2024cites this paper
• Themen – Stellungnahme zur Nutzenbewertung von Mirikizumab (Colitis ulcerosa, vorbehandelte Patient*innen) vom 06. November 2023

  2024cites this paper
• From the updated landscape of the emerging biologics for IBDs treatment to the new delivery systems.

  2023cites this paper
• Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows.

  2023cites this paper
• Amelioration of colitis progression by ginseng-derived exosome-like nanoparticles through suppression of inflammatory cytokines

  2023cites this paper
• Blood-Based Immune Protein Markers of Disease Progression in Murine Models of Acute and Chronic Inflammatory Bowel Disease

  2023cites this paper
• Preclinical species gene expression database: Development and meta-analysis

  2023cites this paper
• Green Solid-Phase (Micro)Extraction of Andrographolides’ from Human Plasma Samples Followed by UHPLC-DAD-QqQ-MS/MS Analysis

  2023cites this paper
• Secreted glucose regulated protein78 ameliorates DSS-induced mouse colitis

  2023cites this paper
• Modulating the Microbiome for Disease Treatment.

  2023cites this paper
• Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study

  2023cites this paper
• IBD disease-modifying therapies: insights from emerging therapeutics.

  2023cites this paper
• Sacral Nerve Stimulation Alleviates Intestinal Inflammation Through Regulating the Autophagy of Macrophages and Activating the Inflammasome Mediated by a Cholinergic Antiinflammatory Pathway in Colitis Rats.

  2023cites this paper
• Mas‐related G protein‐coupled receptors in gastrointestinal dysfunction and inflammatory bowel disease: A review

  2023cites this paper
• The Winning Line Up: Positioning Advanced Therapies for Ulcerative Colitis

  2023cites this paper
• JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases

  2023cites this paper
• Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease

  2023cites this paper
• Mise à jour sur le traitement médicamenteux de la colite ulcéreuse

  2023cites this paper
• Update zur medikamentösen Therapie der Colitis ulcerosa

  2023cites this paper
• Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease

  2023cites this paper
• Personalizing therapy selection in inflammatory bowel disease

  2023cites this paper
• The Role of Seaweed Polysaccharides in Gastrointestinal Health: Protective Effect against Inflammatory Bowel Disease

  2023cites this paper
• Therapeutic Potential of Human Intestinal Organoids in Tissue Repair Approaches in Inflammatory Bowel Diseases

  2023cites this paper
• Characteristics of Facilities With Early and Rapid Ustekinumab Adoption for Patients With Inflammatory Bowel Disease

  2023cites this paper
• Integrin β6 deficiency protects mice from experimental colitis and colitis-associated carcinoma by altering macrophage polarization

  2023cites this paper
• Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

  2023cites this paper
• Development of ADS051, an oral, gut‐restricted, small molecule neutrophil modulator for the treatment of neutrophil‐mediated inflammatory diseases

  2023cites this paper
• Advancements in Inflammatory Bowel Disease: A Narrative Review of Diagnostics, Management, Epidemiology, Prevalence, Patient Outcomes, Quality of Life, and Clinical Presentation

  2023cites this paper
• Novel Small Molecules in IBD: Current State and Future Perspectives

  2023cites this paper
• Mucosal Metabolomic Signatures in Chronic Colitis: Novel Insights into the Pathophysiology of Inflammatory Bowel Disease

  2023cites this paper
• The role of sphingosine-1-phosphate in the gut mucosal microenvironment and inflammatory bowel diseases

  2023cites this paper
• Gut microbiome-based thiamine metabolism contributes to the protective effect of one acidic polysaccharide from Selaginella uncinata (Desv.) Spring against inflammatory bowel disease

  2023cites this paper
• Pre-existing Illness Discrimination in Healthcare: How Barriers to Specialty Medication Effect Public Health Costs and Access

  2023cites this paper
• JAK-gátlók a colitis ulcerosa kezelésében

  2023cites this paper
• Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years

  2023cites this paper
• The metabolic fate of izencitinib, a gut-selective pan-JAK inhibitor, in humans. Identification of unusual fecal metabolites and implications for MIST evaluation

  2023cites this paper
• Recent Advances in Cell‐Based In Vitro Models to Recreate Human Intestinal Inflammation

  2023cites this paper
• Characterization and optimization of variability in a human colonic epithelium culture model

  2023cites this paper
• Pharmacohistory of Cannabis Use—A New Possibility in Future Drug Development for Gastrointestinal Diseases

  2023cites this paper
• Compartment-driven imprinting of intestinal CD4 T cells in inflammatory bowel disease and homeostasis

  2023cites this paper
• Intestinal Ultrasound and Magnetic Resonance Imaging for Monitoring Therapeutic Response in Luminal Crohn's Disease. A Systematic Review.

  2023cites this paper
• Application of Drug Repurposing Approach for Therapeutic Intervention of Inflammatory Bowel Disease.

  2023cites this paper
• Horizon scanning: new and future therapies in the management of inflammatory bowel disease

  2023cites this paper
• Advancements in the Study of Biologic Agents in Comorbidities of Psoriasis: A Literature Review

  2023cites this paper
• Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels

  2023cites this paper
• Choosing Therapies in Ulcerative Colitis

  2023cites this paper
• Pediatric-type follicular lymphoma in a Crohn’s disease patient receiving anti-α4β7-integrin therapy: A case report

  2023cites this paper